Skip to main content

AT-03A-001 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects with Moderate COVID-19

NCT04396106

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects with Moderate COVID-19

Associated Conditions

COVID-19

Principal Investigator

Jason Sniffen

Sponsor

Atea Pharmaceuticals

You are being asked to take part in a clinical research study of an oral drug called AT-527 (a direct-acting antiviral drug). AT-527 is an investigational drug, which means it has not been approved for the treatment of any disease by government health authorities in the United States or other countries. This study will test AT-527 in people with coronavirus disease 2019, the condition for which you are being evaluated.

This study is currently enrolling.